FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2621883146> ?p ?o ?g. }

• W2621883146 endingPage "103" @default.
• W2621883146 startingPage "103" @default.
• W2621883146 abstract "103 Background: CD19-targeted CAR T cells show CR rates of 70-95% in B-ALL. Yet a subset of patients do not respond or relapse due to poor CAR T cell expansion and persistence. We hypothesized that PD-1 checkpoint pathway inhibition may improve CAR T cell expansion, function and persistence. Methods: Four children with relapsed B-ALL treated with murine (CTL019) or humanized (CTL119) anti-CD19 CAR T cells received 1-3 doses of the PD-1 inhibitor pembrolizumab (PEM) for partial/no response or prior history of poor CAR T cell persistence starting 14d-2mo post CAR T cell infusion. Results: PEM increased and/or prolonged detection of circulating CAR T cells in all 4 children, with objective responses in 2/4. It was well tolerated, with fever in 2 pts and no autoimmune toxicity. Pts 1-3 received CTL119 for CD19+ relapse after prior murine CD19 CAR T cells. Pt 1 had 1.2% CD19+ residual disease despite expansion with detectable CTL119 by D28 and received PEM at 2mo for progressive disease with decreasing circulating CTL119. CTL119 became detectable at 0.2% of CD3+ cells by flow cytometry, but disease progressed. Pt 2 had no response after initial CTL119 expansion with a rapid disappearance by D28. After CTL119 reinfusion with PEM added 14d later, circulating CAR T cells remained detectable at 4.4% by D28, but disease progressed with decreased CD19 expression. In Pt 3, prior treatment with both CTL019 and CTL119 produced CR with poor CAR T cell persistence followed by CD19+ relapse. CTL119 reinfusion combined with PEM at D14 resulted in CR with prolonged CTL119 persistence (detectable at D50 compared to loss by D36 after 1 st CTL119 infusion). Pt 4 received PEM for widespread extramedullary (EM) involvement at D28 post CTL019 infusion despite marrow remission. Initial CTL019 expansion peaked at 63% at D10 and fell to 20% at D28. Resurgence of CTL019 expansion, with a 2 nd peak of 70% 11d after PEM, was associated with dramatic reduction in PET-avid disease by 3mo post CTL019. Conclusions: PEM was safely combined with CAR T cells and increased or prolonged CAR T cell detection, with objective responses seen. Immune checkpoint pathways may impact response to CAR T cell treatments and warrant further investigation. Clinical trial information: NCT02374333, NCT02906371." @default.
• W2621883146 created "2017-06-15" @default.
• W2621883146 creator A5008558372 @default.
• W2621883146 creator A5028647628 @default.
• W2621883146 creator A5029979708 @default.
• W2621883146 creator A5033469242 @default.
• W2621883146 creator A5034307197 @default.
• W2621883146 creator A5035811418 @default.
• W2621883146 creator A5041739266 @default.
• W2621883146 creator A5044330314 @default.
• W2621883146 creator A5047973111 @default.
• W2621883146 creator A5052541853 @default.
• W2621883146 creator A5058550252 @default.
• W2621883146 creator A5063117105 @default.
• W2621883146 creator A5066470697 @default.
• W2621883146 creator A5077440294 @default.
• W2621883146 creator A5078139221 @default.
• W2621883146 creator A5082820757 @default.
• W2621883146 creator A5089409657 @default.
• W2621883146 date "2017-05-20" @default.
• W2621883146 modified "2023-10-16" @default.
• W2621883146 title "The effect of pembrolizumab in combination with CD19-targeted chimeric antigen receptor (CAR) T cells in relapsed acute lymphoblastic leukemia (ALL)." @default.
• W2621883146 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.103" @default.
• W2621883146 hasPublicationYear "2017" @default.
• W2621883146 type Work @default.
• W2621883146 sameAs 2621883146 @default.
• W2621883146 citedByCount "74" @default.
• W2621883146 countsByYear W26218831462017 @default.
• W2621883146 countsByYear W26218831462018 @default.
• W2621883146 countsByYear W26218831462019 @default.
• W2621883146 countsByYear W26218831462020 @default.
• W2621883146 countsByYear W26218831462021 @default.
• W2621883146 countsByYear W26218831462022 @default.
• W2621883146 countsByYear W26218831462023 @default.
• W2621883146 crossrefType "journal-article" @default.
• W2621883146 hasAuthorship W2621883146A5008558372 @default.
• W2621883146 hasAuthorship W2621883146A5028647628 @default.
• W2621883146 hasAuthorship W2621883146A5029979708 @default.
• W2621883146 hasAuthorship W2621883146A5033469242 @default.
• W2621883146 hasAuthorship W2621883146A5034307197 @default.
• W2621883146 hasAuthorship W2621883146A5035811418 @default.
• W2621883146 hasAuthorship W2621883146A5041739266 @default.
• W2621883146 hasAuthorship W2621883146A5044330314 @default.
• W2621883146 hasAuthorship W2621883146A5047973111 @default.
• W2621883146 hasAuthorship W2621883146A5052541853 @default.
• W2621883146 hasAuthorship W2621883146A5058550252 @default.
• W2621883146 hasAuthorship W2621883146A5063117105 @default.
• W2621883146 hasAuthorship W2621883146A5066470697 @default.
• W2621883146 hasAuthorship W2621883146A5077440294 @default.
• W2621883146 hasAuthorship W2621883146A5078139221 @default.
• W2621883146 hasAuthorship W2621883146A5082820757 @default.
• W2621883146 hasAuthorship W2621883146A5089409657 @default.
• W2621883146 hasConcept C126322002 @default.
• W2621883146 hasConcept C147483822 @default.
• W2621883146 hasConcept C203014093 @default.
• W2621883146 hasConcept C2776090121 @default.
• W2621883146 hasConcept C2777701055 @default.
• W2621883146 hasConcept C2778461978 @default.
• W2621883146 hasConcept C2778957590 @default.
• W2621883146 hasConcept C2779823535 @default.
• W2621883146 hasConcept C2780057760 @default.
• W2621883146 hasConcept C2780850621 @default.
• W2621883146 hasConcept C3875195 @default.
• W2621883146 hasConcept C553184892 @default.
• W2621883146 hasConcept C71924100 @default.
• W2621883146 hasConcept C8891405 @default.
• W2621883146 hasConceptScore W2621883146C126322002 @default.
• W2621883146 hasConceptScore W2621883146C147483822 @default.
• W2621883146 hasConceptScore W2621883146C203014093 @default.
• W2621883146 hasConceptScore W2621883146C2776090121 @default.
• W2621883146 hasConceptScore W2621883146C2777701055 @default.
• W2621883146 hasConceptScore W2621883146C2778461978 @default.
• W2621883146 hasConceptScore W2621883146C2778957590 @default.
• W2621883146 hasConceptScore W2621883146C2779823535 @default.
• W2621883146 hasConceptScore W2621883146C2780057760 @default.
• W2621883146 hasConceptScore W2621883146C2780850621 @default.
• W2621883146 hasConceptScore W2621883146C3875195 @default.
• W2621883146 hasConceptScore W2621883146C553184892 @default.
• W2621883146 hasConceptScore W2621883146C71924100 @default.
• W2621883146 hasConceptScore W2621883146C8891405 @default.
• W2621883146 hasIssue "15_suppl" @default.
• W2621883146 hasLocation W26218831461 @default.
• W2621883146 hasOpenAccess W2621883146 @default.
• W2621883146 hasPrimaryLocation W26218831461 @default.
• W2621883146 hasRelatedWork W1800085677 @default.
• W2621883146 hasRelatedWork W2076035400 @default.
• W2621883146 hasRelatedWork W2474714119 @default.
• W2621883146 hasRelatedWork W2621883146 @default.
• W2621883146 hasRelatedWork W2805748792 @default.
• W2621883146 hasRelatedWork W3180295291 @default.
• W2621883146 hasRelatedWork W3186173966 @default.
• W2621883146 hasRelatedWork W4281961745 @default.
• W2621883146 hasRelatedWork W4283362546 @default.
• W2621883146 hasRelatedWork W4284885518 @default.
• W2621883146 hasVolume "35" @default.
• W2621883146 isParatext "false" @default.
• W2621883146 isRetracted "false" @default.
• W2621883146 magId "2621883146" @default.

• next